For: | Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] |
---|---|
URL: | https://www.wjgnet.com/2150-5330/full/v5/i2/54.htm |
Number | Citing Articles |
1 |
Cristiano Pagnini, Francesca Menasci, Federico Desideri, Vito D. Corleto, Gianfranco Delle Fave, Emilio Di Giulio. Endoscopic scores for inflammatory bowel disease in the era of ‘mucosal healing’: Old problem, new perspectives. Digestive and Liver Disease 2016; 48(7): 703 doi: 10.1016/j.dld.2016.03.006
|
2 |
Joshua M. Royal, Micaela A. Reeves, Nobuyuki Matoba. Repeated Oral Administration of a KDEL-Tagged Recombinant Cholera Toxin B Subunit Effectively Mitigates DSS Colitis despite a Robust Immunogenic Response. Toxins 2019; 11(12): 678 doi: 10.3390/toxins11120678
|
3 |
Klaus R. Herrlinger, Eduard F. Stange. Twenty‐five years of biologicals in IBD: What´s all the hype about?. Journal of Internal Medicine 2021; 290(4): 806 doi: 10.1111/joim.13345
|
4 |
Jon Florholmen. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2015; 50(1): 43 doi: 10.3109/00365521.2014.977943
|
5 |
Gary R. Lichtenstein. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Digestive Diseases and Sciences 2016; 61(2): 358 doi: 10.1007/s10620-015-3897-0
|
6 |
Silvia Nardelli, Laura Francesca Pisani, Gian Eugenio Tontini, Maurizio Vecchi, Luca Pastorelli. MMX® technology and its applications in gastrointestinal diseases. Therapeutic Advances in Gastroenterology 2017; 10(7): 545 doi: 10.1177/1756283X17709974
|
7 |
Antonio Tursi. Managing Patients with Ulcerative Colitis with Infliximab in Primary and Referral Gastroenterology Centers. Inflammatory Bowel Diseases 2014; 20(12): E24 doi: 10.1097/MIB.0000000000000252
|